Skip to content

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

Menu

Home
About
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
ACCESS MY PROFILE

Menu

Home
About
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
ACCESS MY PROFILE

[denovo_breadcrumbs]

Advances in asthma management – Strategies and innovations

Questionnaire

To access this module, please register or login:

Login or Register

Advances in asthma management – Strategies and innovations
Advances in asthma management – Strategies and innovations

Time limit: 0

Questionnaire Summary

0 of 10 Questions completed

Questions:

Information

You have already completed the questionnaire before. Hence you can not start it again.

Questionnaire is loading…

You must sign in or sign up to start the questionnaire.

You must first complete the following:

Results

Questionnaire complete. Results are being recorded.

Results

0 of 10 Questions answered correctly

Time has elapsed

You have reached 0 of 0 point(s), (0)

Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)

Categories

Not categorized 0%

Regrettably, you have failed to achieve the 70% pass mark required by the accrediting HPCSA.
Please read/watch the module carefully and try once more – remember, only two tries are allowed!
PLEASE NOTE: You will no longer receive a fail confirmation email.
Congratulations on successfully completing this FREE CPD module!
For HPCSA members only: Do not load your certificate on HPCSA, as deNovo Medica uploads these weekly. Please allow 5-10 working days for the CPD activity to reflect on your HPCSA profile.
For non-HPCSA members: The above button allows you to download and print your CPD certificate to submit to your council yourself.
PLEASE NOTE: You will no longer receive a pass confirmation email! Visit YOUR PROFILE to find all your CPD certificates and activities completed.

1
2
3
4
5
6
7
8
9
10

Current
Review
Answered
Correct
Incorrect

Question 1 of 10
1. Question
1. Among reasons underlying poor asthma control are:
A. Poor adherence to regular SABA
Correct Incorrect Correct answer

B. Poor inhaler technique
Correct Incorrect Correct answer

C. Both of the above
Correct Incorrect Correct answer

D. None of the above
Correct Incorrect Correct answer
Question 2 of 10
2. Question
2. Factors that have been associated with increased asthma mortality include:
A. Overuse of SABA
Correct Incorrect Correct answer

B. Underuse of ICS
Correct Incorrect Correct answer

C. LABA monotherapy
Correct Incorrect Correct answer

D. All of the above
Correct Incorrect Correct answer
Question 3 of 10
3. Question
3. Independent of ICS use, an increased risk of severe asthma exacerbations has been associated with annual SABA use of:
A. >1 canister
Correct Incorrect Correct answer

B. ≥2 canisters
Correct Incorrect Correct answer

C. ≥3 canisters
Correct Incorrect Correct answer

D. None of the above
Correct Incorrect Correct answer
Question 4 of 10
4. Question
4. In South Africa, ≥3 SABA canisters are prescribed per year for 75% of asthma patients.
A. True
Correct Incorrect Correct answer

B. False
Correct Incorrect Correct answer
Question 5 of 10
5. Question
5. Compared with salbutamol as needed in patients with asthma, real-world data from NOVEL-START of budesonide-formoterol as needed demonstrate:
A. Superiority for prevention of exacerbations
Correct Incorrect Correct answer

B. Comparatively delayed time to first severe exacerbation
Correct Incorrect Correct answer

C. Both of the above
Correct Incorrect Correct answer

D. None of the above
Correct Incorrect Correct answer
Question 6 of 10
6. Question
6. A meta-analysis of budesonide-formoterol reliever in mild asthma has demonstrated clinical benefit when compared with:
A. SABA reliever
Correct Incorrect Correct answer

B. ICS maintenance plus SABA reliever
Correct Incorrect Correct answer

C. Both of the above
Correct Incorrect Correct answer

D. None of the above
Correct Incorrect Correct answer
Question 7 of 10
7. Question
7. A meta-analysis of budesonide-formoterol reliever in mild asthma has demonstrated similar rates of emergency department admissions as with patients using ICS maintenance plus SABA reliever.
A. True
Correct Incorrect Correct answer

B. False
Correct Incorrect Correct answer
Question 8 of 10
8. Question
8. A study of adults and children with moderate-to-severe asthma found that, when compared with as-needed salbutamol alone, the risk of severe asthma exacerbation with as-needed salbutamol-budesonide was:
A. Significantly lower
Correct Incorrect Correct answer

B. Significantly higher
Correct Incorrect Correct answer

D. Similar
Correct Incorrect Correct answer
Question 9 of 10
9. Question
9. GINA 2024 recommendations prefer as-needed low-dose ICS-formoterol as:
A. The only treatment for mild asthma
Correct Incorrect Correct answer

B. The only treatment for moderate-to-severe asthma
Correct Incorrect Correct answer

C. As reliever for moderate-to-severe asthma
Correct Incorrect Correct answer

D. All of the above
Correct Incorrect Correct answer

E. A and C only
Correct Incorrect Correct answer
Question 10 of 10
10. Question
10. For the treatment of SEA, tezepelumab targets:
A. IL-4Rα
Correct Incorrect Correct answer

B. Only IL-5
Correct Incorrect Correct answer

C. IL-4 and IL-5
Correct Incorrect Correct answer

D. IgE
Correct Incorrect Correct answer

All Rights Reserved 2025 © deNovo Medica (Pty) Ltd in South Africa. The content on this website is intended for healthcare related professionals unless stated otherwise.

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Login

Accessing this module requires a login. Please enter your credentials below!

Username or Email Address

Password

Remember Me

Lost Your Password?